Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bevan

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Human & Experimental Toxicology|November 5, 1997
Paracetamol poisoning in the north east of England: presentation, early management and outcomeS H Thomas, J E Horner, K Chew, et al.
The Journal of Allergy and Clinical Immunology|May 8, 2021
Targeting androgen signaling in ILC2s protects from IL-33-driven lung inflammation, independently of KLRG1Eve Blanquart, Audrey Mandonnet, Marion Mars, et al.
Human & Experimental Toxicology|June 1, 1996
Presentation of poisoned patients to accident and emergency departments in the north of EnglandS H Thomas, L Bevan, S Bhattacharyya, et al.
Molecular Oncology|September 22, 2014
The co-chaperone p23 promotes prostate cancer motility and metastasisLaia Querol Cano, Derek N Lavery, Soraya Sin, et al.
Human & Experimental Toxicology|November 1, 1996
Factors affecting hospital admission and length of stay of poisoned patients in the north east of EnglandS H Thomas, S Lewis, L Bevan, et al.
Journal of the American Chemical Society|June 4, 2021
A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate CancerScott Lovell, Leran Zhang, Thomas Kryza, et al.
Cancer Research|December 21, 2010
FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growthGreg N Brooke, Rachel L Culley, D Alwyn Dart, et al.
Oncogene|February 6, 2026
Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancerG N Brooke, D A Leach, R L Culley, et al.
British Journal of Cancer|April 19, 2023
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancerTheodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, et al.
British Journal of Cancer|February 14, 2024
Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancerTheodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Human & Experimental Toxicology|November 5, 1997
Paracetamol poisoning in the north east of England: presentation, early management and outcomeS H Thomas, J E Horner, K Chew, et al.
The Journal of Allergy and Clinical Immunology|May 8, 2021
Targeting androgen signaling in ILC2s protects from IL-33-driven lung inflammation, independently of KLRG1Eve Blanquart, Audrey Mandonnet, Marion Mars, et al.
Human & Experimental Toxicology|June 1, 1996
Presentation of poisoned patients to accident and emergency departments in the north of EnglandS H Thomas, L Bevan, S Bhattacharyya, et al.
Molecular Oncology|September 22, 2014
The co-chaperone p23 promotes prostate cancer motility and metastasisLaia Querol Cano, Derek N Lavery, Soraya Sin, et al.
Human & Experimental Toxicology|November 1, 1996
Factors affecting hospital admission and length of stay of poisoned patients in the north east of EnglandS H Thomas, S Lewis, L Bevan, et al.
Journal of the American Chemical Society|June 4, 2021
A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate CancerScott Lovell, Leran Zhang, Thomas Kryza, et al.
Cancer Research|December 21, 2010
FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growthGreg N Brooke, Rachel L Culley, D Alwyn Dart, et al.
Oncogene|February 6, 2026
Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancerG N Brooke, D A Leach, R L Culley, et al.
British Journal of Cancer|April 19, 2023
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancerTheodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, et al.
British Journal of Cancer|February 14, 2024
Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancerTheodora A Constantin, Anabel Varela-Carver, Kyle K Greenland, et al.
Pageof 14